Stock analysis, AI verdict, fundamentals & technical signals
Rating: NEUTRAL
Price: $3.83 Analyst target: $32.20 Upside: 740.73%
Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of new clean-surface nanotechnology (CSN) therapies. The company is headquartered in Salt Lake City, Utah.
See the full interactive analysis & chart →Informational only — not investment advice.